HomeAscidian and Exegenesis Bio enter strategic agreement to accelerate development of RNA...

Ascidian and Exegenesis Bio enter strategic agreement to accelerate development of RNA Exon editors with next generation AAV capsids

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, and Exegenesis Bio, a global gene therapy company with proprietary AI-enabled optimised AAV capsid discovery capabilities, have announced a strategic agreement combining Ascidian’s RNA exon editing technology with Exegenesis Bio’s capsid engineering and discovery workflows.

The partnership enables novel delivery approaches tailored to the specific clinical needs of individual programmes. Collaborative scientific work underway will accelerate in vivo data generation and progression toward clinical development for a suite of RNA exon editors targeting devastating diseases.

Achieving effective delivery at a tolerable dose remains a major bottleneck in the development of genetic therapies.

Engineered, tissue-specific AAV capsids can direct therapeutic payloads to target cell types and minimise exposure to non-target cells, improving patient safety, reducing cost of goods, and maximising therapeutic benefit.

To identify the right delivery capabilities for its RNA exon editing platform, Ascidian conducted a global search for AAV capsid engineering partners.

The resulting agreement brings together complementary technologies to evaluate combinations of RNA exon editors and next-generation capsids suited to the needs of individual programmes.

A flexible framework to scale programme-specific delivery

Under the agreement, the companies will evaluate Exegenesis Bio’s AAV capsids and capsid discovery capabilities against the delivery requirements of individual RNA exon editing programmes.

Rigorous scientific considerations and defined target capsid profiles will guide the selection of complementary RNA exon editor-capsid combinations for in vivo and clinical development.

Ascidian will carry out further execution of resulting RNA exon editor-capsid combinations.

The non-exclusive framework allows Ascidian to work with other capsid providers as needed and to select clinical and commercial manufacturing partners based on programme needs.

Exegenesis Bio retains the ability to independently, or with partners, further develop the relevant capsids outside of Ascidian’s RNA exon editor programmes.

Specific target indications, programme details, and financial terms are not being disclosed.

- Advertisment -
- Advertisment -

Most Popular

Popular categories